# TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Source: https://onco.cc/trials/nct06206174/  
OnCo record `nct06206174` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TGRX-814 in non-Hodgkin lymphoma, acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes / neoplasms, run by Shenzhen TargetRx Co., Ltd., now recruiting.

## Summary

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies is a phase 1/2 interventional study registered as NCT06206174 by Shenzhen TargetRx Co., Ltd., with 30 participants planned, started 2024-03-06 and due to reach its primary completion in 2025-02-28. Interventions recorded: TGRX-814.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06206174
- Phase: 1/2
- Setting: A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies
- Sponsor: Shenzhen TargetRx Co., Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06206174: https://clinicaltrials.gov/study/NCT06206174

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/)

---
JSON: https://onco.cc/api/v1/entities/nct06206174.json